Cervical cancer screening in developing countries at a crossroad: Emerging technologies and policy choices

World Journal of Clinical Oncology

Volumn 6, Issue 6, 2015, Pages 281-290

  Catarino, Rosa ^a   Petignat, Patrick ^a   Dongui, Gabriel ^b   Vassilakos, Pierre ^c  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b University Hospital of Yopougon   (Côte d’Ivoire)

^c WHO Collaborating Centre in Education and Research in Human Reproduction   (Switzerland)

Author keywords

Cervical cancer screening; Human papillomavirus testing; Low and middle income countries

Indexed keywords

EID: 84951964782     PISSN: None     EISSN: 22184333     Source Type: Journal    
DOI: 10.5306/wjco.v6.i6.281     Document Type: Review

References (85)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-E386 [PMID: 25220842 DOI: 10.1002/ijc.29210]
2. Bruni L, Barrionuevo-Rosas L, Albero G, Aldea M, Serrano B, Valencia S, Brotons M, Mena M, Cosano R, Mu-oz J, Bosch FX, de Sanjosé S, Castellsagué X. ICO Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases Reports. Accessed 2015 March 20. Available from: URL: http://www.hpvcentre.net/statistics/reports/XWX.pdf
3. LaMontagne DS, Barge S, Le NT, Mugisha E, Penny ME, Gandhi S, Janmohamed A, Kumakech E, Mosqueira NR, Nguyen NQ, Paul P, Tang Y, Minh TH, Uttekar BP, Jumaan AO. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ 2011; 89: 821-830B [PMID: 22084528 DOI: 10.2471/ BLT.11.089862]
4. World Health Organization. Burden of cervical cancer globally. WHO/ICO Information Center on HPV and Cervical Cancer. Accessed 2011. Available from: URL: http: /www.hpvcentre.net/ dataquery.php
5. Ngugi CW, Boga H, Muigai AW, Wanzala P, Mbithi JN. Factors affecting uptake of cervical cancer early detection measures among women in Thika, Kenya. Health Care Women Int 2012; 33: 595-613 [PMID: 22681745 DOI: 10.1080/07399332.2011.646367]
6. Winkler J, Bingham A, Coffey P, Handwerker WP. Women's participation in a cervical cancer screening program in northern Peru. Health Educ Res 2008; 23: 10-24 [PMID: 17229778 DOI: 10.1093/her/cyl156]
7. Sancho-Garnier H, Khazraji YC, Cherif MH, Mahnane A, Hsairi M, El Shalakamy A, Osgul N, Tuncer M, Jumaan AO, Seoud M. Overview of cervical cancer screening practices in the extended Middle East and North Africa countries. Vaccine 2013; 31 Suppl 6: G51-G57 [PMID: 24331820 DOI: 10.1016/j.vaccine.2012.06.046]
8. Sankaranarayanan R, Budukh AM, Rajkumar R. Effective screening programmes for cervical cancer in low- and middleincome developing countries. Bull World Health Organ 2001; 79: 954-962 [PMID: 11693978]
9. Department of Cytology and Gynaecological Pathology, Postgraduate Institute of Medical Education, and Research, Chandigarh, India. Guidelines for Cervical Cancer Screening Programme. [accessed 2006 Jun]. Available from: URL: http:// screening.iarc.fr/doc/WHO-India-CCSP-guidelines-2005.pdf
10. Aswathy S, Quereshi MA, Kurian B, Leelamoni K. Cervical cancer screening: Current knowledge & amp; practice among women in a rural population of Kerala, India. Indian J Med Res 2012; 136: 205-210 [PMID: 22960886]
11. Nygård M. Screening for cervical cancer: when theory meets reality. BMC Cancer 2011; 11: 240 [PMID: 21668947 DOI: 10.118 6/1471-2407-11-240]
12. Arbyn M, Rebolj M, De Kok IM, Fender M, Becker N, O'Reilly M, Andrae B. The challenges of organising cervical screening programmes in the 15 old member states of the European Union. Eur J Cancer 2009; 45: 2671-2678 [PMID: 19695867 DOI: 10.1016/ j.ejca.2009.07.016]
13. Austoker J. Cancer prevention in primary care. Screening for cervical cancer. BMJ 1994; 309: 241-248 [PMID: 7980803 DOI: 10.1136/bmj.309.6950.315]
14. Denny L, Quinn M, Sankaranarayanan R. Chapter 8: Screening for cervical cancer in developing countries. Vaccine 2006; 24 Suppl 3: S3/71-S3/77 [PMID: 16950020 DOI: 10.1016/j.vaccine.2006.05.121]
15. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, Szarewski A, Birembaut P, Kulasingam S, Sasieni P, Iftner T. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006; 119: 1095-1101 [PMID: 16586444 DOI: 10.1002/ijc.21955]
16. Visual inspection with acetic acid for cervical-cancer screening: test qualities in a primary-care setting. University of Zimbabwe/ JHPIEGO Cervical Cancer Project. Lancet 1999; 353: 869-873 [PMID: 10093978 DOI: 10.1016/S0140-6736(98)07033-0]
17. Denny L, Kuhn L, Pollack A, Wainwright H, Wright TC. Evaluation of alternative methods of cervical cancer screening for resource-poor settings. Cancer 2000; 89: 826-833 [PMID: 10951346 DOI: 10.1002/1097-0142(20000815)89: 4<826::AIDCNCR15> 3.0.CO;2-5]
18. Arbyn M, Sankaranarayanan R, Muwonge R, Keita N, Dolo A, Mbalawa CG, Nouhou H, Sakande B, Wesley R, Somanathan T, Sharma A, Shastri S, Basu P. Pooled analysis of the accuracy of five cervical cancer screening tests assessed in eleven studies in Africa and India. Int J Cancer 2008; 123: 153-160 [PMID: 18404671 DOI: 10.1002/ijc.23489]
19. Sauvaget C, Fayette JM, Muwonge R, Wesley R, Sankaranarayanan R. Accuracy of visual inspection with acetic acid for cervical cancer screening. Int J Gynaecol Obstet 2011; 113: 14-24 [PMID: 21257169 DOI: 10.1016/j.ijgo.2010.10.012]
20. Sankaranarayanan R, Anorlu R, Sangwa-Lugoma G, Denny LA. Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa. Vaccine 2013; 31 Suppl 5: F47-F52 [PMID: 24331747 DOI: 10.1016/ j.vaccine.2012.06.066]
21. Wright TC, Kuhn L. Alternative approaches to cervical cancer screening for developing countries. Best Pract Res Clin Obstet Gynaecol 2012; 26: 197-208 [PMID: 22385539 DOI: 10.1016/ j.bpobgyn.2011.11.004]
22. Gaffikin L, Blumenthal PD, Emerson M, Limpaphayom K. Safety, acceptability, and feasibility of a single-visit approach to cervicalcancer prevention in rural Thailand: a demonstration project. Lancet 2003; 361: 814-820 [PMID: 12642047 DOI: 10.1016/ S0140-6736(03)12707-9]
23. Blumenthal PD, Gaffikin L, Deganus S, Lewis R, Emerson M, Adadevoh S. Cervical cancer prevention: safety, acceptability, and feasibility of a single-visit approach in Accra, Ghana. Am J Obstet Gynecol 2007; 196: 407.e1-e8; discussion 407.e8-e9 [PMID: 17403438]
24. Sankaranarayanan R, Basu P, Wesley RS, Mahe C, Keita N, Mbalawa CC, Sharma R, Dolo A, Shastri SS, Nacoulma M, Nayama M, Somanathan T, Lucas E, Muwonge R, Frappart L, Parkin DM. Accuracy of visual screening for cervical neoplasia: Results from an IARC multicentre study in India and Africa. Int J Cancer 2004; 110: 907-913 [PMID: 15170675 DOI: 10.1002/ijc.20190]
25. Bigoni J, Gundar M, Tebeu PM, Bongoe A, Schäfer S, Fokom- Domgue J, Catarino R, Tincho EF, Bougel S, Vassilakos P, Petignat P. Cervical cancer screening in sub-Saharan Africa: a randomized trial of VIA versus cytology for triage of HPV-positive women. Int J Cancer 2015; 137: 127-134 [PMID: 25420434 DOI: 10.1002/ ijc.29353]
26. Murillo R, Luna J, Gamboa O, Osorio E, Bonilla J, Cendales R. Cervical cancer screening with naked-eye visual inspection in Colombia. Int J Gynaecol Obstet 2010; 109: 230-234 [PMID: 20347442 DOI: 10.1016/j.ijgo.2010.01.019]
27. Li N, Shi JF, Franceschi S, Zhang WH, Dai M, Liu B, Zhang YZ, Li LK, Wu RF, De Vuyst H, Plummer M, Qiao YL, Clifford G. Different cervical cancer screening approaches in a Chinese multicentre study. Br J Cancer 2009; 100: 532-537 [PMID: 19127262 DOI: 10.1038/sj.bjc.6604840]
28. Sankaranarayanan R, Esmy PO, Rajkumar R, Muwonge R, Swaminathan R, Shanthakumari S, Fayette JM, Cherian J. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet 2007; 370: 398-406 [PMID: 17679017 DOI: 10.1016/S0140-6736(07)61195-7]
29. Sankaranarayanan R, Gaffikin L, Jacob M, Sellors J, Robles S. A critical assessment of screening methods for cervical neoplasia. Int J Gynaecol Obstet 2005; 89 Suppl 2: S4-S12 [PMID: 15823266 DOI: 10.1016/j.ijgo.2005.01.009]
30. Massad LS, Jeronimo J, Katki HA, Schiffman M. The accuracy of colposcopic grading for detection of high-grade cervical intraepithelial neoplasia. J Low Genit Tract Dis 2009; 13: 137-144 [PMID: 19550210 DOI: 10.1097/LGT.0b013e31819308d4]
31. Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, Arbyn M, Kitchener H, Segnan N, Gilham C, Giorgi-Rossi P, Berkhof J, Peto J, Meijer CJ. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014; 383: 524-532 [PMID: 24192252 DOI: 10.1016/S0140-6736(13)62218-7]
32. Vassilakos P, Catarino R, Frey Tirri B, Petignat P. Cervical cancer screening in Switzerland: time to rethink the guidelines. Swiss Med Wkly 2015; 145: w14112 [PMID: 25664576 DOI: 10.4414/ smw.2015.14112]
33. Phillips S, Garland SM, Tan JH, Quinn MA, Tabrizi SN. Comparison of the Roche Cobas(®) 4800 HPV assay to Digene Hybrid Capture 2, Roche Linear Array and Roche Amplicor for Detection of High-Risk Human Papillomavirus Genotypes in Women undergoing treatment for cervical dysplasia. J Clin Virol 2015; 62: 63-65 [PMID: 25542473 DOI: 10.1016/j.jcv.2014.11.017]
34. Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, Arbyn M, Bosch FX, Cuzick J, Dillner J, Heideman DA, Snijders PJ. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009; 124: 516-520 [PMID: 18973271 DOI: 10.1002/ijc.24010]
35. Monsonego J, Hudgens MG, Zerat L, Zerat JC, Syrjänen K, Halfon P, Ruiz F, Smith JS. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study. Int J Cancer 2011; 129: 691-701 [PMID: 20941740 DOI: 10.1002/ijc.25726]
36. Castle PE, Stoler MH, Wright TC, Sharma A, Wright TL, Behrens CM. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol 2011; 12: 880-890 [PMID: 21865084 DOI: 10.1016/S1470-2045(11)70188-7]
37. Tjalma WA, Depuydt CE. Cervical cancer screening: which HPV test should be used-L1 or E6/E7? Eur J Obstet Gynecol Reprod Biol 2013; 170: 45-46 [PMID: 23932300 DOI: 10.1016/ j.ejogrb.2013.06.027]
38. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlée F, Franco EL. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007; 357: 1579-1588 [PMID: 17942871 DOI: 10.1056/NEJMoa071430]
39. Ogilvie GS, Patrick DM, Schulzer M, Sellors JW, Petric M, Chambers K, White R, FitzGerald JM. Diagnostic accuracy of self collected vaginal specimens for human papillomavirus compared to clinician collected human papillomavirus specimens: a metaanalysis. Sex Transm Infect 2005; 81: 207-212 [PMID: 15923286 DOI: 10.1136/sti.2004.011858]
40. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, Hingmire S, Malvi SG, Thorat R, Kothari A, Chinoy R, Kelkar R, Kane S, Desai S, Keskar VR, Rajeshwarkar R, Panse N, Dinshaw KA. HPV screening for cervical cancer in rural India. N Engl J Med 2009; 360: 1385-1394 [PMID: 19339719 DOI: 10.1056/NEJMoa0808516]
41. Goldie SJ, Kuhn L, Denny L, Pollack A, Wright TC. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA 2001; 285: 3107-3115 [PMID: 11427139 DOI: 10.1001/jama.285.24.3107]
42. Shi JF, Canfell K, Lew JB, Zhao FH, Legood R, Ning Y, Simonella L, Ma L, Kang YJ, Zhang YZ, Smith MA, Chen JF, Feng XX, Qiao YL. Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study. BMC Cancer 2011; 11: 239 [PMID: 21668946 DOI: 10.118 6/1471-2407-11-239]
43. Catarino R, Vassilakos P, Stadali-Ullrich H, Royannez-Drevard I, Guillot C, Petignat P. Feasibility of at-home self-sampling for HPV testing as an appropriate screening strategy for nonparticipants in Switzerland: preliminary results of the DEPIST study. J Low Genit Tract Dis 2015; 19: 27-34 [PMID: 25148227 DOI: 10.1097/ LGT.0000000000000051]
44. Dzuba IG, Díaz EY, Allen B, Leonard YF, Lazcano Ponce EC, Shah KV, Bishai D, Lorincz A, Ferris D, Turnbull B, Hernández Avila M, Salmerón J. The acceptability of self-collected samples for HPV testing vs. the pap test as alternatives in cervical cancer screening. J Womens Health Gend Based Med 2002; 11: 265-275 [PMID: 11988136 DOI: 10.1089/152460902753668466]
45. Snijders PJ, Verhoef VM, Arbyn M, Ogilvie G, Minozzi S, Banzi R, van Kemenade FJ, Heideman DA, Meijer CJ. High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening. Int J Cancer 2013; 132: 2223-2236 [PMID: 22907569 DOI: 10.1002/ijc.27790]
46. Untiet S, Vassilakos P, McCarey C, Tebeu PM, Kengne-Fosso G, Menoud PA, BoulvainZ M, Navarria I, Petignat P. HPV self-sampling as primary screening test in sub-Saharan Africa: implication for a triaging strategy. Int J Cancer 2014; 135: 1911-1917 [PMID: 24615324 DOI: 10.1002/ijc.28834]
47. Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A, Salmerón J, Uribe P, Velasco-Mondragón E, Nevarez PH, Acosta RD, Hernández-Avila M. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a communitybased randomised controlled trial. Lancet 2011; 378: 1868-1873 [PMID: 22051739 DOI: 10.1016/S0140-6736(11)61522-5]
48. Petignat P, Faltin DL, Bruchim I, Tramèr MR, Franco EL, Coutlée F. Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis. Gynecol Oncol 2007; 105: 530-535 [PMID: 17335880 DOI: 10.1016/j.ygyno.2007.01.023]
49. Gravitt PE, Belinson JL, Salmeron J, Shah KV. Looking ahead: a case for human papillomavirus testing of self-sampled vaginal specimens as a cervical cancer screening strategy. Int J Cancer 2011; 129: 517-527 [PMID: 21384341 DOI: 10.1002/ijc.25974]
50. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, Minucci D, Naldoni C, Rizzolo R, Schincaglia P, Volante R, Zappa M, Zorzi M, Cuzick J, Segnan N. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 2008; 100: 492-501 [PMID: 18364502 DOI: 10.1093/ jnci/djn065]
51. Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, Anttila A. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J Natl Cancer Inst 2009; 101: 1612-1623 [PMID: 19903804 DOI: 10.1093/jnci/djp367]
52. Tjalma WA, Arbyn M, Paavonen J, van Waes TR, Bogers JJ. Prophylactic human papillomavirus vaccines: the beginning of the end of cervical cancer. Int J Gynecol Cancer 2004; 14: 751-761 [PMID: 15361181 DOI: 10.1111/j.1048-891X.2004.014505.x]
53. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, Garcia FA, Moriarty AT, Waxman AG, Wilbur DC, Wentzensen N, Downs LS, Spitzer M, Moscicki AB, Franco EL, Stoler MH, Schiffman M, Castle PE, Myers ER. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012; 62: 147-172 [PMID: 22422631 DOI: 10.3322/ caac.21139]
54. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007; 370: 890-907 [PMID: 17826171 DOI: 10.1016/S0140-6736(07)61416-0]
55. Muwonge R, Wesley RS, Nene BM, Shastri SS, Jayant K, Malvi SG, Thara S, Sankaranarayanan R. Evaluation of cytology and visual triage of human papillomavirus-positive women in cervical cancer prevention in India. Int J Cancer 2014; 134: 2902-2909 [PMID: 24272364 DOI: 10.1002/ijc.28627]
56. Snijders PJ, Steenbergen RD, Heideman DA, Meijer CJ. HPVmediated cervical carcinogenesis: concepts and clinical implications. J Pathol 2006; 208: 152-164 [PMID: 16362994 DOI: 10.1002/path.1866]
57. McLaughlin-Drubin ME, Münger K. Oncogenic activities of human papillomaviruses. Virus Res 2009; 143: 195-208 [PMID: 19540281 DOI: 10.1016/j.virusres.2009.06.008]
58. Steenbergen RD, Snijders PJ, Heideman DA, Meijer CJ. Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions. Nat Rev Cancer 2014; 14: 395-405 [PMID: 24854082 DOI: 10.1038/nrc3728]
59. Dasari S, Wudayagiri R, Valluru L. Cervical cancer: Biomarkers for diagnosis and treatment. Clin Chim Acta 2015; 445: 7-11 [PMID: 25773118 DOI: 10.1016/j.cca.2015.03.005]
60. Ibeanu OA. Molecular pathogenesis of cervical cancer. Cancer Biol Ther 2011; 11: 295-306 [PMID: 21239888 DOI: 10.4161/ cbt.11.3.14686]
61. Dockter J, Schroder A, Hill C, Guzenski L, Monsonego J, Giachetti C. Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions. J Clin Virol 2009; 45 Suppl 1: S55-S61 [PMID: 19651370 DOI: 10.1016/S1386-6532(09)70009-5]
62. Qiao YL, Jeronimo J, Zhao FH, Schweizer J, Chen W, Valdez M, Lu P, Zhang X, Kang LN, Bansil P, Paul P, Mahoney C, Berard- Bergery M, Bai P, Peck R, Li J, Chen F, Stoler MH, Castle PE. Lower cost strategies for triage of human papillomavirus DNApositive women. Int J Cancer 2014; 134: 2891-2901 [PMID: 24248915 DOI: 10.1002/ijc.28616]
63. Benevolo M, Vocaturo A, Mottolese M, Mariani L, Vocaturo G, Marandino F, Sperduti I, Rollo F, Antoniani B, Donnorso RP. Clinical role of p16INK4a expression in liquid-based cervical cytology: correlation with HPV testing and histologic diagnosis. Am J Clin Pathol 2008; 129: 606-612 [PMID: 18343788 DOI: 10.1309/BEPQXTCQD61RGFMJ]
64. Cuschieri K, Wentzensen N. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 2008; 17: 2536-2545 [PMID: 18842994 DOI: 10.1158/1055-9965. EPI-08-0306]
65. Tsoumpou I, Arbyn M, Kyrgiou M, Wentzensen N, Koliopoulos G, Martin-Hirsch P, Malamou-Mitsi V, Paraskevaidis E. p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat Rev 2009; 35: 210-220 [PMID: 19261387 DOI: 10.1016/ j.ctrv.2008.10.005]
66. McLaughlin-Drubin ME, Crum CP, Münger K. Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming. Proc Natl Acad Sci USA 2011; 108: 2130-2135 [PMID: 21245294 DOI: 10.1073/pnas.1009933108]
67. Lajer CB, Garnæs E, Friis-Hansen L, Norrild B, Therkildsen MH, Glud M, Rossing M, Lajer H, Svane D, Skotte L, Specht L, Buchwald C, Nielsen FC. The role of miRNAs in human papilloma virus (HPV)-associated cancers: bridging between HPV-related head and neck cancer and cervical cancer. Br J Cancer 2012; 106: 1526-1534 [PMID: 22472886 DOI: 10.1038/bjc.2012.109]
68. Pereira PM, Marques JP, Soares AR, Carreto L, Santos MA. MicroRNA expression variability in human cervical tissues. PLoS One 2010; 5: e11780 [PMID: 20668671 DOI: 10.1371/journal. pone.0011780]
69. Lee JW, Choi CH, Choi JJ, Park YA, Kim SJ, Hwang SY, Kim WY, Kim TJ, Lee JH, Kim BG, Bae DS. Altered MicroRNA expression in cervical carcinomas. Clin Cancer Res 2008; 14: 2535-2542 [PMID: 18451214 DOI: 10.1158/1078-0432.CCR-07-1231]
70. Deftereos G, Corrie SR, Feng Q, Morihara J, Stern J, Hawes SE, Kiviat NB. Expression of mir-21 and mir-143 in cervical specimens ranging from histologically normal through to invasive cervical cancer. PLoS One 2011; 6: e28423 [PMID: 22194833 DOI: 10.1371/journal.pone.0028423]
71. Martinez I, Gardiner AS, Board KF, Monzon FA, Edwards RP, Khan SA. Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene 2008; 27: 2575-2582 [PMID: 17998940 DOI: 10.1038/sj.onc.1210919]
72. Hu X, Schwarz JK, Lewis JS, Huettner PC, Rader JS, Deasy JO, Grigsby PW, Wang X. A microRNA expression signature for cervical cancer prognosis. Cancer Res 2010; 70: 1441-1448 [PMID: 20124485 DOI: 10.1158/0008-5472.CAN-09-3289]
73. Melar-New M, Laimins LA. Human papillomaviruses modulate expression of microRNA 203 upon epithelial differentiation to control levels of p63 proteins. J Virol 2010; 84: 5212-5221 [PMID: 20219920 DOI: 10.1128/JVI.00078-10]
74. Han Y, Xu GX, Lu H, Yu DH, Ren Y, Wang L, Huang XH, Hou WJ, Wei ZH, Chen YP, Cao YG, Zhang R. Dysregulation of miRNA-21 and their potential as biomarkers for the diagnosis of cervical cancer. Int J Clin Exp Pathol 2015; 8: 7131-7139 [PMID: 26261606]
75. Fernandez AF, Rosales C, Lopez-Nieva P, Graña O, Ballestar E, Ropero S, Espada J, Melo SA, Lujambio A, Fraga MF, Pino I, Javierre B, Carmona FJ, Acquadro F, Steenbergen RD, Snijders PJ, Meijer CJ, Pineau P, Dejean A, Lloveras B, Capella G, Quer J, Buti M, Esteban JI, Allende H, Rodriguez-Frias F, Castellsague X, Minarovits J, Ponce J, Capello D, Gaidano G, Cigudosa JC, Gomez-Lopez G, Pisano DG, Valencia A, Piris MA, Bosch FX, Cahir-McFarland E, Kieff E, Esteller M. The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Res 2009; 19: 438-451 [PMID: 19208682 DOI: 10.1101/gr.083550.108]
76. Bryant D, Tristram A, Liloglou T, Hibbitts S, Fiander A, Powell N. Quantitative measurement of Human Papillomavirus type 16 L1/L2 DNA methylation correlates with cervical disease grade. J Clin Virol 2014; 59: 24-29 [PMID: 24268385 DOI: 10.1016/ j.jcv.2013.10.029]
77. Qiu C, Zhi Y, Shen Y, Gong J, Li Y, Li X. High-resolution melting analysis of HPV-16L1 gene methylation: A promising method for prognosing cervical cancer. Clin Biochem 2015; 48: 855-859 [PMID: 25982893 DOI: 10.1016/j.clinbiochem.2015.05.006]
78. Pun PB, Liao YP, Su PH, Wang HC, Chen YC, Hsu YW, Huang RL, Chang CC, Lai HC. Triage of high-risk human papillomaviruspositive women by methylated POU4F3. Clin Epigenetics 2015; 7: 85 [PMID: 26300990 DOI: 10.1186/s13148-015-0122-0]
79. Pinto AP, Degen M, Villa LL, Cibas ES. Immunomarkers in gynecologic cytology: the search for the ideal 'biomolecular Papanicolaou test'. Acta Cytol 2012; 56: 109-121 [PMID: 22378072 DOI: 10.1159/000335065]
80. Conesa-Zamora P, Doménech-Peris A, Orantes-Casado FJ, Ortiz- Reina S, Sahuquillo-Frías L, Acosta-Ortega J, García-Solano J, Pérez-Guillermo M. Effect of human papillomavirus on cell cycle-related proteins p16, Ki-67, Cyclin D1, p53, and ProEx C in precursor lesions of cervical carcinoma: a tissue microarray study. Am J Clin Pathol 2009; 132: 378-390 [PMID: 19687314 DOI: 10.1309/AJCPO0WY1VIFCYDC]
81. Borras G, Molina R, Xercavins J, Ballesta A, Iglesias J. Tumor antigens CA 19.9, CA 125, and CEA in carcinoma of the uterine cervix. Gynecol Oncol 1995; 57: 205-211 [PMID: 7729735 DOI: 10.1006/gyno.1995.1126]
82. Dasari S, Rajendra W, Valluru L. Evaluation of soluble CD44 protein marker to distinguish the premalignant and malignant carcinoma cases in cervical cancer patients. Med Oncol 2014; 31: 139 [PMID: 25064733 DOI: 10.1007/s12032-014-0139-9]
83. Kulkarni S, Rader JS, Zhang F, Liapis H, Koki AT, Masferrer JL, Subbaramaiah K, Dannenberg AJ. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res 2001; 7: 429-434 [PMID: 11234900]
84. Van Trappen PO, Steele D, Lowe DG, Baithun S, Beasley N, Thiele W, Weich H, Krishnan J, Shepherd JH, Pepper MS, Jackson DG, Sleeman JP, Jacobs IJ. Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis. J Pathol 2003; 201: 544-554 [PMID: 14648657 DOI: 10.1002/ path.1467]
85. Suprynowicz FA, Disbrow GL, Krawczyk E, Simic V, Lantzky K, Schlegel R. HPV-16 E5 oncoprotein upregulates lipid raft components caveolin-1 and ganglioside GM1 at the plasma membrane of cervical cells. Oncogene 2008; 27: 1071-1078 [PMID: 17704805 DOI: 10.1038/sj.onc.1210725]